JP2024521316A5 - - Google Patents
Info
- Publication number
- JP2024521316A5 JP2024521316A5 JP2023572689A JP2023572689A JP2024521316A5 JP 2024521316 A5 JP2024521316 A5 JP 2024521316A5 JP 2023572689 A JP2023572689 A JP 2023572689A JP 2023572689 A JP2023572689 A JP 2023572689A JP 2024521316 A5 JP2024521316 A5 JP 2024521316A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- independently
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208923P | 2021-06-09 | 2021-06-09 | |
| US63/208,923 | 2021-06-09 | ||
| PCT/US2022/032707 WO2022261235A1 (en) | 2021-06-09 | 2022-06-08 | Non-peptide targeted therapeutics and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521316A JP2024521316A (ja) | 2024-05-31 |
| JP2024521316A5 true JP2024521316A5 (enExample) | 2025-06-16 |
Family
ID=84425531
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572689A Pending JP2024521316A (ja) | 2021-06-09 | 2022-06-08 | 非ペプチド標的治療薬及びその使用 |
| JP2023576169A Pending JP2024521450A (ja) | 2021-06-09 | 2022-06-08 | 非ペプチド標的治療およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023576169A Pending JP2024521450A (ja) | 2021-06-09 | 2022-06-08 | 非ペプチド標的治療およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20240408247A1 (enExample) |
| EP (2) | EP4351653A4 (enExample) |
| JP (2) | JP2024521316A (enExample) |
| CN (1) | CN117377495A (enExample) |
| WO (2) | WO2022261221A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023396827A1 (en) * | 2022-12-13 | 2025-06-19 | Crinetics Pharmaceuticals, Inc. | Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof |
| TW202613146A (zh) * | 2024-06-11 | 2026-04-01 | 美商克林提克斯醫藥股份有限公司 | 生長抑素亞型-2受體(sst2r)非肽藥物偶聯物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT405906B (de) * | 1997-03-14 | 1999-12-27 | Irene Dr Virgolini | Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie |
| EP1219305A1 (en) * | 2000-12-27 | 2002-07-03 | Bayer Aktiengesellschaft | Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units |
| EP1401427A4 (en) * | 2001-06-06 | 2004-12-01 | Agouron Pharma | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF, PROCESSES FOR THE PREPARATION THEREOF |
| CN100356984C (zh) * | 2002-01-24 | 2007-12-26 | 巴内斯－朱威胥医院 | 整联蛋白靶向的影像剂 |
| WO2003068769A1 (en) * | 2002-02-12 | 2003-08-21 | Pfizer Inc. | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh) |
| US7771727B2 (en) * | 2002-03-01 | 2010-08-10 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| CA2556752C (en) * | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| BRPI0510909A2 (pt) * | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
| US9630976B2 (en) | 2012-07-03 | 2017-04-25 | Ono Pharmaceutical Co., Ltd. | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
| US10131682B2 (en) * | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| WO2014184682A1 (en) * | 2013-04-19 | 2014-11-20 | Oslo Universitetssykehus Hf | Radiolabeled gnrh antagonists as pet imaging agents |
| CA2925651A1 (en) | 2013-09-30 | 2015-04-02 | Ono Pharmaceutical Co., Ltd. | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof |
| CN116726190A (zh) * | 2015-06-20 | 2023-09-12 | 杭州多禧生物科技有限公司 | 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物 |
| CA3050094C (en) * | 2017-01-12 | 2024-01-02 | Radiomedix Inc. | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes |
| MX2019009419A (es) | 2017-02-08 | 2019-10-02 | Ono Pharmaceutical Co | Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo. |
| NZ757081A (en) | 2017-03-16 | 2023-03-31 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| KR102724812B1 (ko) * | 2017-04-05 | 2024-11-01 | 코넬 유니버시티 | 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물 |
| TWI852944B (zh) | 2018-09-18 | 2024-08-21 | 美商克林提克斯醫藥股份有限公司 | 生長抑制素(somatostatin)調節劑及其用途 |
-
2022
- 2022-06-08 JP JP2023572689A patent/JP2024521316A/ja active Pending
- 2022-06-08 EP EP22820971.4A patent/EP4351653A4/en active Pending
- 2022-06-08 JP JP2023576169A patent/JP2024521450A/ja active Pending
- 2022-06-08 CN CN202280037485.4A patent/CN117377495A/zh active Pending
- 2022-06-08 US US18/566,733 patent/US20240408247A1/en active Pending
- 2022-06-08 WO PCT/US2022/032691 patent/WO2022261221A1/en not_active Ceased
- 2022-06-08 WO PCT/US2022/032707 patent/WO2022261235A1/en not_active Ceased
- 2022-06-08 US US18/566,887 patent/US20240285628A1/en active Pending
- 2022-06-08 EP EP22820979.7A patent/EP4351654A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102320942B1 (ko) | 표적 치료제 | |
| JP5878546B2 (ja) | ｓＧＣ刺激剤 | |
| CN101370497B (zh) | 包含parp抑制剂和细胞毒性剂的联合产品及用途 | |
| CN105517548B (zh) | 用于治疗过度增生性病症的mek抑制剂和erk抑制剂的组合 | |
| JP6367822B2 (ja) | Ｅｐ４アンタゴニストとしての新規ベンゾイミダゾール誘導体 | |
| JP2021502388A (ja) | Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法 | |
| AU2016307882A1 (en) | Compositions comprising a PI3K inhibitor and an HDAC inhibitor | |
| KR20160126078A (ko) | 표적 치료제 | |
| TW201740979A (zh) | 熱休克蛋白（ｈｓｐ）９０抑制劑藥物共軛物 | |
| KR20170043561A (ko) | 셀리넥소의 다형태 | |
| SG193842A1 (en) | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) | |
| BRPI0622285A2 (pt) | compostos aprefeiçoados farmacocineticamente | |
| WO2012173521A2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2020517598A (ja) | Ｅｒｋ１／２阻害剤としての６−ピリミジン−イソインドール誘導体 | |
| RU2351330C2 (ru) | Применение эпотилонов в лечении заболеваний головного мозга, ассоциированных с пролиферативными процессами | |
| WO2013012886A1 (en) | Carbocyanines for g-quadruplex dna stabilization and telomerase inhibition | |
| CN109789127A (zh) | 吲哚啉酮化合物的用途 | |
| US20060235006A1 (en) | Combinations, methods and compositions for treating cancer | |
| US7879868B2 (en) | Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents | |
| WO2011116287A1 (en) | Ccr5 modulators for treating hiv | |
| CN104602691B (zh) | Vegfr‑3抑制剂用于治疗肝细胞癌的用途 | |
| CN101791312A (zh) | 一类四氢异喹啉衍生物的用途 | |
| US8293764B2 (en) | Compositions and methods for disruption of BRCA2-Rad51 interaction | |
| JP7130180B2 (ja) | 子宮内膜症の処置のためのインドールの新規誘導体 | |
| US20250313537A1 (en) | Benzodiazepine analogs and methods of use in treating cancer |